Intercept Pharmaceuticals, Inc. (ICPT) News
Filter ICPT News Items
ICPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ICPT News Highlights
- ICPT's 30 day story count now stands at 15.
- Over the past 18 days, the trend for ICPT's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about ICPT are DRUG, AKYA and BEAT.
Latest ICPT News From Around the Web
Below are the latest news stories about INTERCEPT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ICPT as an investment opportunity.
Intercept (ICPT) Stock Down on FDA Committee Update on NDAIntercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May. |
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) down to US$672m market cap, but institutional owners may not be as affected after a year of 8.0% returnsKey Insights Institutions' substantial holdings in Intercept Pharmaceuticals implies that they have significant... |
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another ObstacleIntercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble. |
Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 MonthsIntercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance. |
Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASHAdvisory Committee Meeting scheduled for May 19, 2023 PDUFA Target Action Date is June 22, 2023 MORRISTOWN, N.J., March 10, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) will discuss Intercept’s new drug a |
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on March 14, 2023. Meeting Details For investors attending the conference who wish to meet with the Intercept |
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q4 2022 Earnings Call TranscriptIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q4 2022 Earnings Call Transcript March 2, 2023 Operator: Good day and thank you for standing by. Welcome to the Intercept Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. […] |
Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales IncreaseIntercept (ICPT) posts a narrower loss in Q4 due to higher revenues. |
Q4 2022 Intercept Pharmaceuticals Inc Earnings CallQ4 2022 Intercept Pharmaceuticals Inc Earnings Call |
Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue EstimatesIntercept (ICPT) delivered earnings and revenue surprises of 20.75% and 0.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |